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Aneuploidy, an abnormal chromosome number, is a frequent characteristic of malignant cells, leading to
the suggestion that aneuploidy drives tumorigenesis. In a recent issue of Science, Williams et al. identified
a paradoxical relationship between aneuploidy and its linkage to tumorigenesis: chromosome gains in
nontransformed cells are antiproliferative, despite frequently occurring in human tumors.Aneuploidy Is a Hallmark
of Tumor Cells
Aneuploidy occurs in 90% of solid hu-
man tumors and 75% of hematopoietic
cancers (Weaver and Cleveland, 2006)
and was recognized as a common char-
acteristic of tumor cells 118 years ago.
This finding led to Boveri’s hypothesis in
1902 and 1914 that aneuploid cells are
the progenitors of tumors.
Experimental testingofBoveri’s ideahas
beenhamperedby thedifficultyofgenerat-
ing aneuploidy without causing additional,
confounding defects. Early experiments
used drugs to induce aneuploidy, many
of which were subsequently shown to
induce DNA damage. More recent experi-
ments have used mouse models that gen-
erate high degrees of whole chromosomal
aneuploidy from reduced levels of compo-
nents of the mitotic checkpoint (also
known as the spindle assembly check-
point). This checkpoint is the major cell-
cycle control pathway in mitosis; it acts to
prevent aneuploidy by delaying cell-cycle
advance through mitosis prior to success-
ful attachment of every chromosome to the
mitotic spindle (Musacchio and Salmon,
2007). Mice that express reduced levels
ofmitoticcheckpoint componentsdevelop
aneuploidy but have divergent tumor phe-
notypes: some are tumor prone, while
others are not. These divergent outcomes
are likely due to the fact that most of these
mitotic checkpoint components are
expressed throughout the cell cycle and
participate in diverse cellular processes,
including apoptosis, transcriptional re-
pression, and chromosomal rearrange-
ments (Weaver and Cleveland, 2006).
However, CENP-E, a tether betweenspindle microtubules and centromeres, is
a component of the mitotic checkpoint
that apparently functions exclusively in
chromosome segregation. Reduction of
CENP-E promotes some types of tumors
and inhibits others (Weaver et al., 2007).
Chromosome Gains, but Not
Losses, Cause a Proliferative
Disadvantage
Following this preceding work, Williams
et al. (2008) created aneuploidmurine em-
bryonic fibroblasts (MEFs) of a defined
karyotype. These cells contained a single
extra copy of chromosome 1, 13, 16, or 19
and were created by mating wild-type
animals with animals containing two dif-
ferent Robertsonian translocations involv-
ing the same chromosome. In each case,
gain of a single whole chromosome
yielded trisomic MEFs that grew more
slowly than diploid MEFs (Williams et al.,
2008). These results from cells that have
a stable 2n + 1 aneuploid genome are
consistent with results from cells that
exhibit chromosomal instability (CIN).
CIN cells are aneuploid due to recurring
gains and losses of chromosomes during
multiple divisions. In vivo, splenocytes
and peripheral blood lymphocytes that
exhibit aneuploidy and CIN due to reduc-
tion in CENP-E proliferate well after loss of
one or a few chromosomes. However,
cells that have gained one or a few chro-
mosomes are almost completely elimi-
nated from the cycling population. This
proliferative disadvantage is observable,
albeit more subtle, in MEFs with reduced
levels of CENP-E, where chromosome
losses outnumber gains in the cells that
continue cycling (Weaver et al., 2007).Cancer Cell 14,A proliferative disadvantage following
chromosome gain, but not chromosome
loss, seems to be a consistent finding.
Developing neuronal precursors (Kaushal
et al., 2003), embryonic stem cells lacking
the BRCA1 tumor suppressor (Shen et al.,
1998), MEFs that express a mutant form
of the adenomatous polyposis coli (APC)
tumor suppressor, and MEFs that are
heterozygous for the mitotic checkpoint
component BubR1 (Rao et al., 2005)
have all been observed to grow more
slowly after chromosome gain. This is
also true after gain of even a single chro-
mosome in budding yeast (Torres et al.,
2007). Thus, chromosome gains consis-
tently cause a growth defect in multiple
species and contexts.
So what underlies the growth disadvan-
tage from an extra copy of a single
chromosome? For the four mouse chro-
mosomes tested by Williams et al.
(2008), the simplest view is that increased
expression of each of the many genes on
the additional chromosome (the smallest
of which encodes 678 known genes)
disrupts the balance of gene products re-
quired for normal cell growth and cycling.
It is also possible that chromosome gains
cause a proliferative defect due to
increased levels of DNA damage or
unfolded proteins. Whatever the mecha-
nism, the available data suggest that it is
surprisingly sensitive, since gain of a
single small chromosome is sufficient to
engage it. It is also unclear at what stage
of the cell cycle chromosome gains cause
delay, as accumulation at a particular
cell-cycle stage was not observed (Wil-
liams et al., 2008). Nor did trisomic
MEFs display an increase in cell death orDecember 9, 2008 ª2008 Elsevier Inc. 431
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Previewssenescence. Interestingly, MEFs that
have gained chromosomes continue to
cycle after loss of p53, suggesting that
the proliferative disadvantage caused by
chromosome gain is at least partly p53




The fact that chromosome gains, but not
chromosome losses, cause a proliferative
defect raises a paradox in terms of their
contribution to tumorigenesis, because
most tumor cells exhibit chromosome
gains (Figure 1A). For all tumors, including
carcinomas, hematopoietic cancers, and
sarcomas, >70% of aneuploid tumor cells
exhibit chromosome gains (Figure 1A,
left). While spontaneous immortalization
of each of the MEFs triploid for defined
chromosomes was accompanied by
acquisition of a near tetraploid state (Wil-
liams et al., 2008), what this means for
tumorigenesis is unsettled, as this is not
the case for hematopoietic malignancies
and only a minority of carcinomas and
sarcomas are near tetraploid (Figure 1A,
right).
Aneuploidy Can Promote and Inhibit
Immortalization and Tumorigenesis
The effect of chromosome gain on spon-
taneous immortalization appears to de-
pend on which chromosome is involved.
An extra copy of chromosome 13 delays
immortalization, an extra copy of chromo-
some 16 may accelerate immortalization,
and an extra copy of chromosome
19 has no effect (Williams et al., 2008).
This is reminiscent of the finding that an-
euploidy due to reduction in CENP-E
promotes spontaneous spleen and lung
tumors but inhibits genetically and chem-
ically induced tumors (Weaver et al.,
2007). Similarly, increasing the rate of
chromosome missegregation in animals
expressing the multiple intestinal neopla-
sia allele of APC by reducing levels of
the mitotic checkpoint component
BubR1 causes increased rates of colon
tumors but decreased rates of small-
intestine tumors (Rao et al., 2005). Thus,
a consistent insight is that aneuploidy
can both promote and inhibit immortaliza-
tion, transformation, and tumorigenesis,
depending on the context of other genetic
changes. Unsurprisingly, the effects of
aneuploidy are likely to be dependent on
the specific chromosomes that have
been gained or lost (Figure 1B).
Conclusions: Not All Aneuploid
Cells Are Created Equal
Aneuploidy hasbeenproposed as a cause
of cancer for over 100 years, based on the
fact that it is a strikingly common charac-
teristic of tumors. It is now clear that the
effects of aneuploidy are more complex
than initially proposed. Aneuploidy can
drive tumorigenesis, but it does not nec-
essarily do so. In some contexts,
Figure 1. Chromosome Gains Commonly Occur in Human Tumors but Cause Proliferative Defects in Primary Cells
(A) Chromosome gains are the most common type of aneuploidy found in human tumors. The number of chromosomes per cell in carcinomas (top), hematopoi-
etic cancers (middle), and sarcomas (bottom) is shown. Chromosome numbers were obtained from the Mitelman Database of Chromosome Aberrations in
Cancer (Mitelman et al., 2006). Note that some cells with 46 chromosomes have gained and lost chromosomes and are no longer diploid.
(B) Different types of aneuploidy have distinct effects on cell growth and tumorigenesis. Cells that have lost chromosomes (left) or exhibit continuing chromosomal
instability (CIN) (middle) do not have growth defects. Chromosome gains (right) cause a proliferative disadvantage in primary cells, probably from increased levels
of expression of the many genes encoded by the additional chromosome. Spontaneous immortalization can be accompanied by tetraploidization, which
is probably the result of cytokinesis failure, as observed byWilliams et al. (2008). However, tetraploidization is not a requirement for immortalization; for example,
MEFs lacking the p19/ARF tumor suppressor are immortal but contain a near diploid karyotype.432 Cancer Cell 14, December 9, 2008 ª2008 Elsevier Inc.
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Previewsaneuploidy actually suppresses tumors. It
is not yet clear why aneuploidy has differ-
ent effects in distinct contexts, but at least
three factors are almost certainly relevant:
(1) the specific combination of chromo-
somes present in a given cell; (2) whether
the cell is stably aneuploid or contains
a karyotype that is evolving due to further
chromosomal missegregation; and (3) the
additional mutations, particularly in onco-
genes and tumor suppressors, that are
retained or lost in the cell. Further experi-
ments will be required to determine which
types of aneuploidy promote tumors,
versus inhibit tumors, in a given context.REFERENCES
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